Huons is set to accelerate Phase 2 clinical trials for its peptide-based dry eye disease drug candidate, 'HUC1-394'.


Huons announced on July 3 that it has successfully completed the enrollment of the first patient for the Phase 2 clinical trial of 'HUC1-394'.

Huons Accelerates Phase 2 Trials of Dry Eye Drug 'HUC1-394'...First Patient Enrolled View original image

After obtaining approval for the Phase 2 clinical trial plan (IND) for HUC1-394 in March, Huons carried out the patient screening process and completed the First Patient In (FPI) as of today. The company plans to begin full-scale collection of clinical data moving forward.


This Phase 2 clinical trial will be conducted at leading medical institutions in Korea, including Severance Hospital at Yonsei University College of Medicine, targeting 150 patients with dry eye disease. Using a multi-center, randomized, double-masked (RCT) design, the trial will evaluate the safety and efficacy of HUC1-394.


Huons aims to reach the Last Patient Last Visit (LPLV) by the second half of next year and plans to announce the Clinical Study Report (CSR) thereafter. If efficacy and safety data are secured in Phase 2, preparations for Phase 3 clinical trials will begin.


Kyungmi Park, Executive Vice President and Head of R&D at Huons, stated, "With the enrollment of the first patient in Phase 2, we will work closely with our research team to accelerate development," adding, "We will do our utmost to provide innovative treatment options for patients with dry eye disease."



Meanwhile, HUC1-394 is a peptide-based eye drop introduced by Huons from Novacell Technology Inc. It works by activating the formyl peptide receptor 2 (FPR2), which is involved in the resolution of inflammation in the body. By not only suppressing inflammation but also bringing inflammatory responses to a normal resolution and repairing damaged tissues, HUC1-394 is expected to provide a fundamental therapeutic effect for dry eye disease as a novel drug candidate.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing